Crinetics Pharmaceuticals (CRNX) Reports In-Line Q4 EPS

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($0.88), in-line with the analyst estimate of ($0.88).

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• DA Davidson Reiterates Buy Rating on Tractor Supply Company (TSCO) Amid Soft Q2 Expectations
• US sending additional aircraft to Middle East as Trump considers widening war against Iran - CNN
• Eve Air Mobility pursues eVTOL certification in Brazil and Europe